Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

New implantable device to prevent sudden cardiac arrest

Northwestern Memorial Hospital heart rhythm specialists recently gave a 34-year-old man a makeshift paramedic—who's always on duty—inside of his chest by implanting a device that did not require X-ray assistance and the usual snaking of wires leading to the heart. In fact, the innovative device rests just beneath the surface of the skin and its components are positioned using the patient's own anatomical landmarks.

13 Aug 2010

TomTec releases new version of 2D Cardiac Performance Analysis package

TomTec launches the latest version of its 2D Cardiac Performance Analysis package as part of TomTec's Image-Arena™ multimodality imaging solution.

11 Aug 2010

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Along with skeletal muscles, it may be important to monitor heart function in patients with spinal muscular atrophy (SMA). These are the findings from a study conducted by Nationwide Children's Hospital and published online ahead of print in Human Molecular Genetics. This is the first study to report cardiac dysfunction in mouse models of SMA.

11 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Study tests new performance intervention to improve heart failure patients in outpatient setting

A study led by UCLA tested a new performance intervention to help improve adherence to national guideline-recommended therapies for heart failure patients in an outpatient setting.

27 Jul 2010

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

Texas Children's Hospital in Houston has performed the hospital's first triple-organ transplant on a 16-year-old Brenham resident. The patient, Taylor Sherrouse, underwent a 13-hour surgery on Tuesday, June 22 to replace her heart, lungs and liver, which had been severely damaged by cystic fibrosis. Taylor is one of only three pediatric patients in the country this decade to receive heart, lungs and liver in one operation.

15 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

New approach in treating heart attack, cardiomyopathy using stem cells

Presenting at the UK National Stem Cell Network annual science conference today (13 July), Professor Michael Schneider describes a new approach to treating heart attack and cardiomyopathy using stem cells.

13 Jul 2010

Cardiac Concepts initiates enrollment in European trial of RespiCardia System for CSA

Cardiac Concepts, Inc., a developer of medical devices to treat Heart Failure patients who experience breathing disturbances during sleep, announced today enrollment of the first European patients in a Pilot Clinical Trial. The purpose of the Pilot Study is to understand the respiratory and cardiac benefits of the RespiCardia™ System when treating a breathing disorder known as Central Sleep Apnea (CSA) in Heart Failure patients.

8 Jul 2010

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.

7 Jul 2010

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the company will pursue a Phase 3 clinical program for its autologous cell therapy for the treatment of critical limb ischemia (CLI) through the U.S. Food and Drug Administration's special protocol assessment (SPA) process. Aastrom is currently completing a Phase 2b clinical trial of its cell therapy in patients with CLI and recently met with FDA officials to discuss plans for the Phase 3 program.

7 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.

29 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Phase 2b RESTORE-CLI clinical trial in patients with CLI reaches statistical significance

Richard J. Powell, M.D., section chief of vascular surgery at the Dartmouth-Hitchcock Medical Center in Lebanon, NH and a principal investigator of the U.S. Phase 2b RESTORE-CLI clinical trial sponsored by Aastrom Biosciences, will present the full results from the interim analysis at today's session of the annual meeting of the Society for Vascular Surgery.

11 Jun 2010

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne.

11 Jun 2010

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

10 Jun 2010

4% of South Asian people carry mutated gene that causes heart failure

One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure.

9 Jun 2010

Cardiomyopathy News and Research

Further Reading

New implantable device to prevent sudden cardiac arrest

TomTec releases new version of 2D Cardiac Performance Analysis package

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Study tests new performance intervention to improve heart failure patients in outpatient setting

First triple-organ transplantation performed on young Brenham resident at Texas Children's Hospital

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

New approach in treating heart attack, cardiomyopathy using stem cells

Cardiac Concepts initiates enrollment in European trial of RespiCardia System for CSA

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Aastrom to pursue Phase 3 CLI clinical program through FDA SPA process

Shire receives FDA approval of Daytrana for ADHD in adolescents

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

St. Jude Medical commences enrollment in LAPTOP-HF study

Phase 2b RESTORE-CLI clinical trial in patients with CLI reaches statistical significance

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

Researchers differentiate human stem cells to become heart cells with cardiomyopathy

4% of South Asian people carry mutated gene that causes heart failure

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News